SARS-CoV-2 antibody responses in solid organ transplant recipients.

Autor: Zervou FN; Department of Medicine, Grossman School of Medicine, New York University, New York City, New York, USA., Ali NM; Department of Medicine, Grossman School of Medicine, New York University, New York City, New York, USA.; Langone Transplant Institute, New York University, New York City, New York, USA., Neumann HJ; Department of Medicine, Grossman School of Medicine, New York University, New York City, New York, USA.; Langone Transplant Institute, New York University, New York City, New York, USA., Madan RP; Department of Medicine, Grossman School of Medicine, New York University, New York City, New York, USA.; Langone Transplant Institute, New York University, New York City, New York, USA.; Department of Pediatrics, New York City, New York, USA., Mehta SA; Department of Medicine, Grossman School of Medicine, New York University, New York City, New York, USA.; Langone Transplant Institute, New York University, New York City, New York, USA.
Jazyk: angličtina
Zdroj: Transplant infectious disease : an official journal of the Transplantation Society [Transpl Infect Dis] 2021 Oct; Vol. 23 (5), pp. e13728. Date of Electronic Publication: 2021 Sep 22.
DOI: 10.1111/tid.13728
Abstrakt: Antibody responses among immunocompromised solid organ transplant recipients (SOT) infected with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) may be diminished compared to the general population and have not been fully characterized. We conducted a cohort study at our transplant center to investigate the rate of seroconversion for SARS-CoV-2 IgG antibodies among SOT recipients who were diagnosed with Coronavirus disease 2019 (COVID-19) and underwent serum SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) testing. The 61 patients who were included in the final analysis underwent initial SARS-CoV-2 IgG testing at a median of 62 days (Interquartile range 55.0-75.0) from symptom onset. Note that, 51 of 61 patients (83.6%) had positive SARS-CoV-2 IgG results, whereas 10 (16.4%) had negative IgG results. Six (60%) out of 10 seronegative patients underwent serial IgG testing and remained seronegative up to 17 weeks post-diagnosis. Use of belatacept in maintenance immunosuppression was significantly associated with negative IgG antibodies to SARS-CoV-2 both in univariate and multivariate analyses (Odds ratio 0.04, p = .01). In conclusion, the majority of organ transplant recipients with COVID-19 in our study developed SARS-CoV-2 antibodies. Further longitudinal studies of the durability and immunologic role of these IgG responses and the factors associated with lack of seroconversion are needed.
(© 2021 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: